WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Exit Postmarket & security

THE TAPE

Axogen to pay $200M cash for BioCircuit and its sutureless NerveTape FDA codifies eight De Novo device types as Class II, three years after granting them Precera Medical buys Additive Metal Services to bring metal injection molding in house Powerful Medical wins a De Novo for AI that flags heart attacks on a 10-second ECG Zenflow says four US centers have run the first commercial Spring cases FDA says it has never authorized a clear aligner sold without a prescription CraniUS clears a patient-specific cranial plate under K261058 FDA clears Emboline's Emboliner, a TAVR filter tested head to head against Sentinel Petal Surgical shows its histotripsy robot and says first-in-human is close Axogen to pay $200M cash for BioCircuit and its sutureless NerveTape FDA codifies eight De Novo device types as Class II, three years after granting them Precera Medical buys Additive Metal Services to bring metal injection molding in house Powerful Medical wins a De Novo for AI that flags heart attacks on a 10-second ECG Zenflow says four US centers have run the first commercial Spring cases FDA says it has never authorized a clear aligner sold without a prescription CraniUS clears a patient-specific cranial plate under K261058 FDA clears Emboline's Emboliner, a TAVR filter tested head to head against Sentinel Petal Surgical shows its histotripsy robot and says first-in-human is close

Convertible note

Glucotrack raises $11.5M in convertible notes at a 22 percent original issue discount

MedDevice Startups Staff · 23 hrs ago · 2 min read · Via Company release

Glucotrack (Nasdaq: GCTK) announced $11.5 million in convertible notes on September 11. The face amount is not the cash. New money is $4.5 million, another $4.5 million is existing notes rolled into the new paper, and a 22 percent original issue discount covers the gap. The notes convert at $3.12 a share and the warrants strike at $7.50. Dawson James Securities was placement agent.

Glucotrack is building a long-term implantable continuous blood glucose monitor, which it describes as an investigational device restricted to research use. Terms like these are what a financing looks like when the product is years from market and the existing holders are the ones rolling over.

Questions & Answers

How much did Glucotrack raise in September 2026?

Glucotrack announced $11.5 million in convertible notes on September 11, 2026. That figure is the face amount: $4.5 million is new cash and $4.5 million is existing notes rolled over, with a 22 percent original issue discount making up the difference.

What are the terms of the Glucotrack convertible note financing?

The Glucotrack notes announced September 11, 2026 carry a 22 percent original issue discount, convert at $3.12 per share, and come with warrant coverage struck at $7.50 per share. Dawson James Securities acted as placement agent.

What is Glucotrack developing?

Glucotrack (Nasdaq: GCTK) is developing a long-term implantable continuous blood glucose monitoring system for people with diabetes. As of September 2026 the company describes the device as investigational and restricted to research use.

← Back to Fundraising